RecruitingPhase 2NCT03684655

Imaging Immune Activation in HIV by PET-MR

Imaging Immune Activation in HIV Infection

Sponsor

CellSight Technologies, Inc.

Enrollment

30 participants

Start Date

Sep 21, 2018

Study Type

INTERVENTIONAL

Conditions

HIV Infections

Summary

This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using advanced brain and body scanning (a combined PET-MRI scan) to investigate how HIV causes ongoing inflammation in the body even in people receiving HIV treatment, with the hope of better understanding long-term health complications in people living with HIV. **You may be eligible if...** - You are over 18 years old - You have HIV infection - You are either currently on HIV medication (antiretroviral therapy), have never taken HIV medication, or have been off HIV medication for at least one week - Your blood counts (platelets, white blood cells) and organ function meet minimum levels **You may NOT be eligible if...** - You have a pacemaker, metal implant, aneurysm clip, non-removable piercing, or severe claustrophobia that makes MRI unsafe - You have a medical condition that would interfere with the scan results - You received immune-modifying therapy (other than HIV vaccines) within the past 60 days - You are pregnant or breastfeeding - You are a woman of childbearing age who is not using effective contraception Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)

\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.